Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Archives of Dermatology

• Publication date

  1980-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHDERM.1980.01640280049016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Drugs Five Years Later: Methotrexate

  1977cited by this paper
• Systemic Chemotherapy For Psoriasis: A National Survey

  1976cited by this paper
• Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study.

  1976cited by this paper
• A prospective study of the effects of weekly oral methotrexate on liver biopsy

  1975cited by this paper
• Effects of methotrexate on the liver in psoriasis.

  1974cited by this paper
• Psoriasis-liver-methotrexate interactions.

  1973cited by this paper
• Methotrexate therapy for psoriasis. Guideline revisions.

  1973cited by this paper
• Hepatotoxicity of long-term methotrexate therapy for psoriasis.

  1973cited by this paper
• One-second biopsy of the liver--problems of its clinical application.

  1970cited by this paper

• Methotrexate

  2022cites this paper
• Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta‐analysis

  2021cites this paper
• Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature

  2020cites this paper
• Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review.

  2020cites this paper
• Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography

  2018cites this paper
• Deficiency of the Mitochondrial NAD Kinase Causes Stress-Induced Hepatic Steatosis in Mice.

  2018cites this paper
• Utility of Transient elastography of liver in patients with Rheumatoid arthritis on methotrexate

  2018cites this paper
• they have served us well. Not yet time to change the guidelines for monitoring methotrexate liver toxicity

  2017cites this paper
• Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.

  2017cites this paper
• Hepatotoxicity Related to Methotrexate

  2013cites this paper
• Prognosis in the Rheumatic Diseases

  2012cites this paper
• S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

  2012cites this paper
• The use of methotrexate in dermatology: a review

  2012cites this paper
• S3‐Leitlinie zur Therapie der Psoriasis vulgaris Update 2011

  2011cites this paper
• Actualités sur le psoriasis lors des Journées Dermatologiques de Paris

  2011cites this paper
• S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

  2011cites this paper
• Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity

  2011cites this paper
• Methotrexate use and alcohol.

  2010cites this paper
• Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

  2010cites this paper
• Foie et méthotrexate

  2008cites this paper
• Dangerous liaisons: drug, host and the environment.

  2007cites this paper
• Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.

  2007cites this paper
• Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris

  2007cites this paper
• Tempting Liver Fibrosis? Long-Term Psoriatic Methotrexate Therapy and Heterozygous α1-Antitrypsin Deficiency

  2006cites this paper
• S3‐Leitlinie zur Therapie der Psoriasis vulgaris

  2006cites this paper
• Monitoring Liver Function during Methotrexate Therapy for Psoriasis

  2005cites this paper
• A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis

  2005cites this paper
• Psoriatic arthritis and psoriasis: need for a multidisciplinary approach.

  2005cites this paper
• Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels.

  2004cites this paper
• Monitoring methotrexate‐induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?

  2004cites this paper
• Pharmacokinetics and Pharmacodynamics of Methotrexate in Non-Neoplastic Diseases

  2003cites this paper
• Comparative Tolerability of Systemic Treatments for Plaque-Type Psoriasis

  2002cites this paper
• Not yet time to change the guidelines for monitoring methotrexate liver toxicity: they have served us well.

  2002cites this paper
• Psoriatic arthritis, methotrexate, and liver toxicity.

  2001cites this paper
• Role of non‐alcoholic steatohepatitis in methotrexate‐induced liver injury

  2001cites this paper
• Liver Biopsy in Psoriatic Arthritis to Detect Methotrexate Hepatotoxicity

  2001cites this paper
• Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease

  2000cites this paper
• Risk-Benefit Assessment of Methotrexate in the Treatment of Severe Psoriasis

  2000cites this paper
• Methotrexate use in rheumatoid arthritis. A Clinician's perspective.

  2000cites this paper
• Methotrexate hepatotoxicity: What is the evidence?

  1998cites this paper
• Methotrexate in Rheumatoid Arthritis

  1997cites this paper
• Methotrexate use in psoriasis and psoriatic arthritis.

  1997cites this paper
• Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.

  1997cites this paper
• Review article: methotrexate in gastroenterology—dangerous villain or simply misunderstood?

  1996cites this paper
• Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease.

  1996cites this paper
• Modifications of PUVA.

  1995cites this paper
• Methotrexate revisited: effects of long‐term treatment in psoriasis

  1994cites this paper
• Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis.

  1993cites this paper
• The pharmacology of methotrexate.

  1991cites this paper
• Prediction of organ system toxicity with antirheumatic drug therapy

  1991cites this paper
• Long-term methotrexate therapy for rheumatoid arthritis.

  1991cites this paper
• Methotrexate and histologic hepatic abnormalities: a meta-analysis.

  1991cites this paper
• Hepatotoxicity in a rat model caused by orally administered methotrexate

  1991cites this paper
• Low‐dose methotrexate therapy and hepatotoxicity The view of the hepatologist

  1991cites this paper
• The Practical Use of Methotrexate in Psoriasis

  1990cites this paper
• The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.

  1990cites this paper
• Interaction of Etretinate with Methotrexate Pharmacokinetics in Psoriatic Patients

  1990cites this paper
• Risk factors of second-line antirheumatic drugs in rheumatoid arthritis.

  1990cites this paper
• Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up

  1990cites this paper
• Methotrexate--the rapidly acting drug.

  1990cites this paper
• Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis.

  1990cites this paper
• The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment.

  1989cites this paper
• Detection of hepatotoxicity associated with methotrexate therapy for psoriasis.

  1989cites this paper
• Short‐term methotrexate administration by low‐dose infusion—does it influence clearance of psoriasis?

  1989cites this paper
• Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples.

  1989cites this paper
• Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findings.

  1989cites this paper
• Immunosuppressive (Cytotoxic) and Immunostimulant Drugs

  1989cites this paper
• Methotrexate in rheumatoid arthritis.

  1988cites this paper
• Dose-dependent Acute Hepatitis Associated with Administration of High Dose Methotrexate

  1988cites this paper
• Hepatotoxicity of Methotrexate in Rheumatic Diseases

  1988cites this paper
• Methotrexate in psoriasis: revised guidelines.

  1988cites this paper
• Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response.

  1987cites this paper
• Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage

  1987cites this paper
• Les hépatites chroniques actives médicamenteuses

  1987cites this paper
• Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study.

  1987cites this paper
• Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis.

  1986cites this paper
• Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study.

  1986cites this paper
• Hepatic Collagen Production in the Rat Is Unaffected by Methotrexate 1

  1986cites this paper
• The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

  1986cites this paper
• Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates.

  1986cites this paper
• A review of methotrexate therapy in Reiter syndrome.

  1985cites this paper
• Methotrexate maintenance therapy and liver damage in psoriasis

  1985cites this paper
• Ultrasound as a screening procedure for methotrexate‐induced hepatic damage in severe psoriasis

  1985cites this paper
• Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis

  1985cites this paper
• Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis.

  1985cites this paper
• Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.

  1985cites this paper
• Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.

  1984cites this paper
• Immunosuppressive therapy for rheumatoid arthritis

  1984cites this paper
• Reappraisal of the use of methotrexate in rheumatic disease.

  1983cites this paper
• Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature.

  1983cites this paper
• Methotrexate and ultraviolet radiation.

  1982cites this paper
• Combined methotrexate-PUVA therapy in the treatment of psoriasis.

  1982cites this paper
• Liver Biopsies v Liver Scans in Methotrexate-Treated Patients With Psoriasis

  1982cites this paper
• Methotrexate guidelines--revised.

  1982cites this paper
• Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis.

  1982cites this paper
• Psoriasis and its treatment.

  1981cites this paper
• Dihydrofolate reductase inhibitors as potential drugs

  1981cites this paper
• Cytostatic and immunosuppressive drugs

  1979cites this paper